and analysts at EvaluateVantage have suggested that CTX001 could become a $1.3 billion product if it gets approved for both indications. In October, CRISPR Therapeutics co-founder Emmanuelle ...

CRISPR Therapeutics (CTX001 for SCD and beta-thalassemia, CTX110 for CAR-T therapy) .Cellecta (CRISPR Knockout Libraries, CRISPR sgRNA Lentiviral Pools) .ToolGen (CRISPR-Cas9 System, Genome ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Friday, Marketbeat ...